Evidence Level
Astragalus has a substantial evidence base in Chinese medical literature and growing international recognition. For immune support, a 2013 meta-analysis of 34 RCTs showed significant improvements in immune markers when astragalus was added to chemotherapy regimens. The anti-aging compound cycloastragenol gained attention when Harley et al. (2011) published a pilot study showing telomerase activation and improved immune cell telomere length. For cardiovascular protection, multiple preclinical and early clinical studies support astragaloside IV for heart failure and myocardial ischemia. A limitation is that much of the clinical research uses astragalus in combination with other TCM herbs, making it difficult to isolate its individual contribution.